Skip to content
Basket0
Basket

Your basket is empty.

Your basket is empty.

view_cart
☰

Metformin + Glibenclamide

Metformin + Glibenclamide
In stock
2.5/400mg · 5/500mg
from A$60.85
Strength
Pack size — the bigger the pack, the cheaper the tablet
A$73.02A$60.85
A$2.03 per tablet

In brief

  • In our pharmacy in Australia you can buy metformin + glibenclamide without a prescription; discreet packaging and delivery options are available, although the medicine is formally prescription‑only and should be used under medical supervision.
  • Metformin + glibenclamide is used to treat type 2 diabetes: glyburide (glibenclamide) stimulates pancreatic insulin secretion (sulfonylurea) and metformin reduces hepatic gluconeogenesis and improves insulin sensitivity, so the combination targets both insulin secretion and insulin resistance.
  • Usual dosing for adults starts at 1.25 mg/250 mg once or twice daily with meals, titrated every 2 weeks as needed; available tablet strengths include 1.25/250 mg, 2.5/500 mg and 5/500 mg, with a usual maximum of 20 mg/2000 mg glyburide/metformin per day.
  • The form of administration is oral tablets taken with food.
  • Gliburide (glibenclamide) begins lowering blood glucose within about 1–3 hours; metformin’s glucose‑lowering effects often emerge over days to weeks, with some improvement within 24–48 hours.
  • Duration of action: glyburide’s effect typically lasts around 12–24 hours per dose; metformin’s glucose‑lowering effect is maintained with regular dosing and persists while treatment continues.
  • Avoid excessive alcohol: alcohol increases the risk of metformin‑associated lactic acidosis and can worsen hypoglycaemia risk with sulfonylureas.
  • The most common side effects are gastrointestinal (nausea, diarrhoea, upset stomach), headache and hypoglycaemia (shakiness, sweating, hunger), the latter especially with missed meals or strenuous activity.
  • Would you like to try metformin + glibenclamide without a prescription?

Basic Metformin + Glibenclamide Information

  • INN (International Nonproprietary Name): Metformin and Glyburide
  • Brand Names Available In Australia: not specified
  • ATC Code: A10BD03
  • Forms & Dosages: oral tablets in strengths 1.25mg/250mg, 2.5mg/500mg and 5mg/500mg
  • Manufacturers In Australia: not specified
  • Registration Status In Australia: not specified
  • OTC / Rx Classification: Prescription only (Rx)

Critical Warnings & Restrictions

Safety-First Summary For Australian Patients

Worried about safety? Metformin + glyburide combines metformin and glyburide and carries two serious risks to watch for.

The glyburide component can cause severe hypoglycaemia, especially with missed meals, exercise or in older patients.

The metformin component carries a risk of lactic acidosis, particularly with significant renal impairment or dehydration.

Prioritise monitoring, avoidance strategies and clear emergency steps when starting or changing therapy.

Key absolute contraindications include severe renal impairment (eGFR <30 ml/min), metabolic acidosis or diabetic ketoacidosis, known hypersensitivity, Type 1 diabetes, and pregnancy or breastfeeding where use is not recommended.

Before starting, check baseline eGFR and liver function tests and document alcohol history and pregnancy status where relevant.

Stop metformin before contrast imaging or major surgery according to local protocols and counsel patients to avoid excessive alcohol.

Advise patients to carry quick-acting glucose, wear medical ID if they have recurrent hypos, and arrange follow-up within 2–4 weeks of initiation.

  • Absolute contraindications: eGFR <30 ml/min; metabolic acidosis/diabetic ketoacidosis; known hypersensitivity; Type 1 diabetes; pregnancy/breastfeeding (not recommended).
  • Relative contraindications: elderly patients, mild-moderate renal impairment, hepatic impairment, alcohol abuse, recent major surgery or trauma.

Pre-initiation screening checklist: baseline eGFR, LFTs, alcohol history, pregnancy test if applicable, medication review for interacting drugs.

Brief flowchart for emergencies: suspected lactic acidosis (severe fatigue, muscle pain, rapid breathing) → stop metformin and seek urgent hospital review.

Brief flowchart for severe hypoglycaemia (loss of consciousness, seizures) → call emergency services and give IV glucose or glucagon per protocol.

Q&A — Can I Drive After Taking It In Australia?

Short answer: Not if you have symptoms of hypoglycaemia or have had recent hypo episodes.

Glyburide can cause hypoglycaemia, which impairs driving ability and reaction times.

Australian road-safety and workplace rules require you to be free of impairment, so avoid driving if you feel shaky, sweaty, confused or light-headed.

If you have recurrent hypos, notify your treating clinician and check reporting requirements for safety‑critical jobs.

Usage Basics

INN, Brand Availability And Legal Classification In Australia

The INN is Metformin and Glyburide, often written as metformin + glibenclamide in clinical notes.

The combination was originally sold as Glucovance in some countries, but generics now dominate the global market.

Examples of international brand names include Glucovance and several Glycomet‑GP or Glyburmet variants in Asia.

In Australia specific brand availability or sponsor listings are not specified here, so check the TGA ARTG database for exact entries before prescribing or ordering.

The product is classified as prescription-only (Rx) under standard regulatory regimes and is TGA‑regulated when supplied in Australia.

PBS listing depends on the exact sponsor and pack size, so confirm PBS subsidy and any authority requirements before dispensing.

  • Definition: INN refers to the generic active ingredients, while brand names are sponsor-specific trade names.
  • Regulatory points: TGA oversight applies; PBS subsidy varies by product and pack; prescription-only status applies.

Consider adding a table mapping brand, sponsor and PBS status on clinic or pharmacy pages to help prescribers and patients check subsidy eligibility.

Dosing Guide

Standard Regimens And Adjustments With Australian Context

Patients commonly ask how to start the combination safely and avoid hypos and GI upset.

Standard adult starting dose is 1.25mg/250mg once or twice daily taken with meals to reduce gastrointestinal effects and lower hypoglycaemia risk.

Dose may be titrated every two weeks according to blood glucose and tolerability up to a maximum of 20mg/2000mg daily (glyburide/metformin).

Always emphasise taking tablets with food and reviewing glucose logs during titration.

Start lower in elderly patients and review renal function regularly; the combination is contraindicated if eGFR falls below 30 ml/min.

Reduce or stop metformin around iodinated contrast procedures or major surgery following local protocols.

  • Titration checklist: start 1.25mg/250mg once daily with food, review fasting and postprandial readings, increase every 2 weeks as needed, monitor for hypoglycaemia.
  • Monitoring schedule: baseline eGFR and LFTs, repeat eGFR at 3 months then every 6–12 months; check HbA1c every 3 months during titration.

Q&A — What If I Miss A Dose?

Take the missed dose as soon as you remember unless it is near the time for your next dose.

Do not double up to make up for a missed dose.

If you are prone to hypoglycaemia, check blood glucose more frequently after a missed dose and follow your hypo action plan.

Interaction Chart

Food, Drink And Common Drug Interactions In Australian Practice

Common patient questions include whether alcohol or other medicines will make the tablet unsafe.

Alcohol increases the risk of lactic acidosis with metformin and can destabilise glucose control, so minimise intake and avoid binge drinking.

Large or unplanned changes in carbohydrate intake can increase hypoglycaemia risk because glyburide stimulates insulin release.

Caffeine effects on blood glucose are variable and not a primary concern for this combination.

Major drug interactions to watch for include other hypoglycaemic agents such as insulin or other sulfonylureas which increase hypo risk.

Cationic drugs that compete for renal excretion, like cimetidine, may raise metformin levels and warrant review.

Iodinated contrast media require pausing metformin around the time of the procedure per local imaging and renal protocol.

  • High-risk combinations: metformin with nephrotoxic drugs, metformin with iodinated contrast, glyburide with other insulin secretagogues or insulin.
  • Interaction severity categories: Major (pause metformin before contrast), Moderate (dose review needed), Minor (monitoring advised).

Suggested actions: stop metformin 48 hours before contrast if the patient has impaired renal function, review antibiotics or antifungals that affect hepatic or renal function, and counsel patients on hypo symptoms when combining with other hypoglycaemics.

User Reports & Trends

Patients in Australia often raise the same themes on ProductReview, health forums and at the pharmacy counter.

Common reports include gastrointestinal side effects attributed to metformin and hypoglycaemia episodes tied to the glyburide component.

Cost and availability are frequent concerns, with many Australians relying on PBS subsidies and price‑sensitive decisions.

There is a trend of patients switching from the combination to metformin alone or to newer fixed‑dose combinations with DPP‑4 or SGLT2 inhibitors due to hypoglycaemia or weight concerns.

  • Common patient-reported issues: GI upset, hypoglycaemia, difficulty with titration, supply interruptions.
  • Service patterns: high trust in pharmacists for counselling and dose adjustments, especially in rural areas.

Clinicians should document hypo episodes in the clinical record and consider pharmacy referrals for adherence support and tailored counselling.

Suggested excerpt box: “I started the combo and felt nausea for a week, then my pharmacist helped me space doses with meals and it improved.”

Access & Purchase Options

Where Australians Get Metformin+Glyburide And Access Pathways

People ask where to buy the combo and whether online ordering is safe and legal.

Outlets include community pharmacies such as Chemist Warehouse, Priceline and TerryWhite Chemmart, hospital pharmacies, and TGA‑regulated online pharmacies.

Telehealth e‑prescriptions can help rural patients access treatment but always confirm PBS eligibility and local sponsor supply before ordering.

Many products are generics, so check the TGA ARTG entry and PBS listing for the specific sponsor and pack to confirm subsidy and availability.

Rural areas may experience stock-outs, so advise early repeats and work with local pharmacists for therapeutic substitution when necessary.

In our online pharmacy, metformin + glibenclamide is available without a prescription, with discreet delivery to Australia in 9-21 days.

  • Purchase checklist: valid prescription (if required in your supply chain), verify PBS listing and authority requirements, counselling from pharmacist on first supply.
  • Documentation to have ready: prescription, Medicare card for PBS claims, any PBS Authority form if required.
Outlet Type Pros Cons
Community Pharmacy Immediate counselling, PBS dispensing Stock may vary
Online Pharmacy Convenience, rural delivery Delivery delays, check ARTG/PBS
Hospital Pharmacy Access during admission, specialist oversight Not for routine community supply

Mechanism & Pharmacology

Simple And Clinical Explanations

Patients often want a one‑line explanation of how metformin + glibenclamide works.

Metformin reduces hepatic glucose production and improves insulin sensitivity, addressing insulin resistance common in Type 2 diabetes.

Glyburide is a sulfonylurea that stimulates pancreatic beta cells to release insulin, helping where insulin secretion is insufficient.

Combining both targets two core defects in Type 2 diabetes: insulin resistance and inadequate insulin release.

Glyburide has a longer action and therefore a higher risk of prolonged hypoglycaemia compared with some other sulfonylureas.

Metformin is primarily renally eliminated and requires eGFR monitoring to reduce lactic acidosis risk.

ATC classification for the combination is A10BD03, indicating a combination of oral blood glucose‑lowering drugs.

  • Mechanism terms defined: insulin resistance — reduced tissue response to insulin; hepatic gluconeogenesis — liver glucose production.
  • Pharmacokinetic highlights: oral absorption, metformin renal excretion, glyburide hepatic metabolism and prolonged insulinotropic effect.

Indications & Off-Label Uses

TGA-Approved Indications And Documented Off-Label Practice

The combination is indicated for adults with Type 2 diabetes as ongoing therapy to maintain glycaemic control.

It is not indicated for Type 1 diabetes, paediatric use, pregnancy or lactation where it is not recommended.

Off‑label use is rare and should only occur under specialist oversight with clear documentation and patient consent.

Newer combinations such as metformin with SGLT2 or DPP‑4 inhibitors are often preferred because of cardiovascular and renal benefits in many patients.

  • Approved use: chronic management of Type 2 diabetes in adults when dual oral therapy is appropriate.
  • Discouraged uses: Type 1 diabetes, pregnancy, lactation, paediatric treatment.

Prescribers considering off‑label use should document the evidence base, obtain informed consent, and outline a monitoring plan for renal function and hypoglycaemia.

Key Clinical Findings

Clinicians ask whether the combination is more effective than monotherapy and whether the benefits outweigh the risks.

Clinical data show the combination lowers HbA1c more than metformin alone in appropriately selected patients.

However, it increases the risk of hypoglycaemia compared with metformin monotherapy because of the sulfonylurea effect.

There are fewer recent Australian randomised controlled trials; much evidence is extrapolated from international studies and observational data up to 2022–2026.

Practical takeaway: use the combination when a dual mechanism is clinically indicated and when renal, hepatic and hypo risk factors have been considered.

  • Primary outcomes to monitor: HbA1c reduction and hypoglycaemia rates.
  • Clinical decision factors: patient comorbidities such as CKD, CVD, age and weight concerns.

References box suggestion: include key trials comparing combination therapy with metformin only and current diabetes guidelines when publishing patient-facing materials.

Alternatives Matrix

PBS-Listed Alternatives And Decision Checklist

When hypoglycaemia or other risks make metformin + glyburide unsuitable, consider alternatives that are PBS-listed and better match patient comorbidities.

Common alternatives include metformin monotherapy (Glucophage, Siofor), other sulfonylureas such as gliclazide or glimepiride, and combination products with DPP‑4 or SGLT2 inhibitors.

Newer agents often have favourable weight and cardiovascular or renal profiles compared with sulfonylurea combinations.

Drug Typical PBS Status Hypoglycaemia Risk Weight Effect Renal Notes
Metformin Monotherapy Often PBS-listed Low Neutral/weight loss Adjust with eGFR decline
Gliclazide PBS-listed options Moderate Neutral/weight gain Use caution in CKD
Sitagliptin/Metformin PBS-listed combinations Low Neutral Adjust per product monograph
Empagliflozin/Metformin May be PBS-listed Low Weight loss CKD limits may apply
  • Clinician checklist: consider cardiovascular or renal disease, hypoglycaemia risk, cost and PBS access, patient preference and weight goals before selecting therapy.

Common Questions

People frequently ask practical questions about alcohol, travel, fasting and imaging.

Can I drink alcohol? Avoid excessive alcohol because it increases lactic acidosis risk with metformin and may destabilise glucose control.

What if I am travelling or fasting? Carry quick‑acting carbohydrates, check glucose more often, take medication with meals when possible and consult your clinician about dose adjustments for prolonged fasting or time‑zone changes.

How to recognise hypoglycaemia? Look for shakiness, sweating, hunger, confusion and palpitations, and treat immediately with fast‑acting carbohydrate followed by a longer‑acting snack.

Do I need to stop before scans or surgery? Stop metformin around iodinated contrast or major surgery according to local hospital and radiology protocols, especially if renal function is impaired.

When to seek urgent care? Severe lethargy, rapid breathing, severe muscle pain or persistent vomiting may indicate lactic acidosis and require immediate assessment.

Question Short Answer
Can I drink alcohol? Minimise intake; avoid binge drinking.
What if I’m fasting? Carry snacks and check glucose; speak to clinician about dose timing.
How to spot hypo? Shaky, sweaty, hungry; treat with quick sugar.
Stop before scans? Pause metformin per protocol around iodinated contrast.

Price & Access Comparison Table

Suggested Content For An Australian Price/Access Table

Prices vary by sponsor, pack size and whether the product is PBS-subsidised.

Include pharmacy/source, typical private price range, PBS subsidy status, prescription requirement and online availability when creating a consumer table.

Note that many international brand names such as Glucovance are now generics and local PBS listing varies by sponsor and pack size, so verify ARTG and PBS entries before publishing prices.

  • Access checklist: confirm prescription, check PBS Authority if needed, offer generic substitution options and plan for rural supply interruptions.
  • Caveat: pricing is variable and subject to change with sponsor supply and PBS arrangements.

Registration & Regulation

TGA Approval, PBS Rules And Practitioner Responsibilities

Check the TGA ARTG entry for the exact product and sponsor to confirm approved indications, warnings and supply status.

The combination is prescription-only and may or may not be PBS-listed depending on the sponsor and pack size.

Prescribers should document the clinical rationale for combination therapy, baseline investigations and monitoring plans including renal review.

Apply PBS authority rules when prescribing subsidised packs and keep records for audit and continuity of care.

Pharmacists must verify ARTG and PBS status before dispensing and provide targeted counselling on contraindications and interactions.

  • Regulatory checks for prescribers: confirm ARTG, check PBS listing and authority requirements, document eGFR and monitoring schedule.
  • Pharmacy checklist: verify sponsor/pack, counsel on hypoglycaemia and lactic acidosis, provide written action plan.

Storage & Handling

Household And Pharmacy Storage In Australian Climate

Store tablets at controlled room temperature (20–25°C) and protect from moisture and heat.

Avoid storing medication in bathrooms or in direct sunlight, and do not leave tablets in vehicles during hot weather.

Transport tablets in their original packaging when travelling to preserve batch and expiry information.

Pharmacies should maintain ambient temperature control, rotate stock, and follow the manufacturer’s storage guidance.

Discard tablets that are discoloured or if packaging is damaged, and encourage patients to return expired medicines to the pharmacy for safe disposal.

  • Household checklist: keep in original pack, away from children and pets, avoid humid rooms.
  • Pharmacy table protocol: ambient control, stock rotation, expiry checks and patient counselling at supply.

Guidelines For Proper Use

Australian Pharmacist Counselling Style And Patient Action Plan

Start counselling by naming the active ingredients: metformin + glyburide, and explain why the combination was chosen.

Cover dosing schedule, taking tablets with meals, and common side effects such as nausea, diarrhoea and possible hypoglycaemia.

Explain red flags that need urgent care: severe hypoglycaemia or signs of lactic acidosis like severe lethargy and rapid breathing.

Emphasise monitoring: baseline eGFR, HbA1c every 3 months while titrating, periodic LFTs and medication review during intercurrent illness.

Provide a practical patient plan: a written medication card listing dose and times, allergy history and emergency contacts.

Give a hypo action plan: fast‑acting carbohydrate (glucose gel, juice), follow‑up snack and instructions on when to seek help or call an ambulance.

Advise when to withhold medication such as around iodinated contrast or major surgery and document this in the record.

  • Printable one-page pharmacist script: baseline checks, dosing, hypo plan, renal monitoring schedule and follow-up appointments.
  • Follow-up prompts: pharmacist call at 1–2 weeks after initiation and clinician review at 3 months to assess HbA1c and tolerability.

Delivery Across Australia

City Region Delivery Time
Sydney New South Wales 9-14 days
Melbourne Victoria 9-14 days
Brisbane Queensland 9-14 days
Perth Western Australia 9-14 days
Adelaide South Australia 9-14 days
Canberra Australian Capital Territory 9-14 days
Hobart Tasmania 9-14 days
Darwin Northern Territory 9-14 days
Gold Coast Queensland 9-14 days
Newcastle New South Wales 9-14 days
Wollongong New South Wales 14-21 days
Geelong Victoria 14-21 days
Cairns Queensland 14-21 days
Townsville Queensland 14-21 days
Albury New South Wales 14-21 days

Final Notes And Practical Reminders

Metformin + glyburide is an established dual‑action oral treatment for adults with Type 2 diabetes where a combination of insulin sensitisation and insulin secretion is needed.

Balance benefits in HbA1c reduction with the recognised increased risk of hypoglycaemia and metformin-associated lactic acidosis in susceptible patients.

Always confirm the exact product’s ARTG and PBS status before prescribing or ordering, and document baseline eGFR and follow-up plans in the patient record.

Pharmacists should provide clear written counselling and a hypo action plan at first supply and during early follow-up calls.

For price or access help, ask the dispensing pharmacist about generic options and PBS authority pathways to lower out-of-pocket cost where possible.

Related products